Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
BeOne Medicines Ltd. (ONC)
Price$358.26Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.34B | $3.81B | $2.46B | $1.42B | $1.18B | $308.9M | $428.2M | $198.2M | $238.4M | $1.1M | $8.8M | $13.0M |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | $1.01B | $238.2M | $357.0M | $169.5M | $233.4M | $1.1M | — | — |
| Gross margin | 87.49% | 84.41% | 84.55% | 79.77% | 85.98% | 77.12% | 83.38% | 85.52% | 97.91% | 100.00% | — | — |
| Research & development | $2.15B | $1.95B | $1.78B | $1.64B | $1.46B | $1.29B | $927.3M | $679.0M | $269.0M | $98.0M | $58.3M | $21.9M |
| Operating expenses | $4.23B | $3.78B | $3.29B | $3.21B | $2.62B | $1.97B | $1.39B | $904.0M | $336.8M | $118.1M | $65.6M | $28.8M |
| Operating income | $447.1M | −$568.2M | −$1.21B | −$1.79B | −$1.44B | −$1.66B | −$959.9M | −$705.8M | −$98.5M | −$117.1M | −$56.7M | −$15.8M |
| Operating margin | 8.37% | −14.91% | −49.12% | −126.40% | −122.31% | −536.69% | −224.16% | −356.05% | −41.30% | −10,940.19% | −643.66% | −120.88% |
| EBITDA | $588.8M | −$396.4M | −$1.12B | −$1.72B | −$1.39B | −$1.63B | −$941.3M | −$695.4M | −$93.7M | −$115.2M | −$55.2M | −$14.2M |
| EBITDA margin | 11.02% | −10.40% | −45.55% | −121.71% | −118.36% | −526.39% | −219.81% | −350.81% | −39.31% | −10,761.78% | −626.13% | −108.94% |
| Net income | $286.9M | −$644.8M | −$881.7M | −$2.00B | −$1.46B | −$1.62B | −$948.6M | −$673.8M | −$93.1M | −$119.2M | −$57.1M | −$18.3M |
| Net profit margin | 5.37% | −16.92% | −35.86% | −141.52% | −123.93% | −526.10% | −221.53% | −339.91% | −39.06% | −11,141.78% | −647.71% | −140.22% |
| Basic EPSper basic share | $0.20 | -$0.47 | -$0.65 | -$1.49 | -$1.21 | -$1.50 | -$1.22 | -$0.93 | -$0.17 | -$0.30 | -$0.52 | -$0.18 |
| Diluted EPSper diluted share | $0.19 | -$0.47 | -$0.65 | -$1.49 | -$1.21 | -$1.50 | -$1.22 | -$0.93 | -$0.17 | -$0.30 | -$0.52 | -$0.18 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BAKER BROS. ADVISORS LP | 8.8M |
PRIMECAP MANAGEMENT CO/CA/ | 5.01M |
Capital International Investors | 4.21M |
FMR LLC | 2.48M |
Capital World Investors | 2.25M |
CITADEL ADVISORS LLC | 1.43M |
Temasek Holdings (Private) Ltd | 845.73K |
PRICE T ROWE ASSOCIATES INC /MD/ | 758.75K |
BlackRock, Inc. | 694.62K |
MILLENNIUM MANAGEMENT LLC | 543.32K |
MORGAN STANLEY | 497.44K |
Siren, L.L.C. | 465K |
BANK OF AMERICA CORP /DE/ | 439.34K |
Baird Financial Group, Inc. | 368.98K |
Man Group plc | 307.46K |
Capital International, Inc./CA/ | 305.48K |
Candriam S.C.A. | 289.74K |
TWO SIGMA INVESTMENTS, LP | 286.55K |
UBS Group AG | 258.59K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 249.76K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 | Wang LaiPresident, Global Head of R&D | SellAmerican Depositary Shares | 1.1K | $276.74 | $295.6K | 0 |
| Jun 23, 2026Form 4 | Wu XiaobinPresident and COO | SellAmerican Depositary Shares | 1.3K | $276.26 | $356.9K | 0 |
| Jun 23, 2026Form 4 | OYLER JOHNChief Executive Officer | SellAmerican Depositary Shares | 320 | $275.10 | $88.0K | 0 |
| Jun 23, 2026Form 4 | OYLER JOHNChief Executive Officer | SellAmerican Depositary Shares | 1.3K | $274.12 | $353.6K | 320 |
| Jun 23, 2026Form 4 | OYLER JOHNChief Executive Officer | SellAmerican Depositary Shares | 1.8K | $273.30 | $491.9K | 1.6K |